Market Overview

CEL-SCI Receives Croatian Government Approval to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer



CEL-SCI Corporation (NYSE: CVM) announced today that it has
received approval from the Health Protection Administration, Ministry of
Health, of the Croatian Republic to begin enrollment of subjects into
the Phase III clinical trial of its investigational cancer immunotherapy
treatment Multikine* (Leukocyte Interleukin, Injection). Croatia is the
ninth country into which CEL-SCI has expanded its global Phase III
trial. The trial is expected to be conducted in about 100 clinical
centers worldwide. CEL-SCI expects to enroll approximately 40 patients
in Croatia through four clinical centers.

CEL-SCI plans to accelerate enrollment in its Phase III clinical trial
for Multikine by adding a large number of clinical centers in the eight
countries where approval to start

See full press release

Posted-In: News Guidance Offerings Contracts Management Global


Related Articles (CVM + CVI)

View Comments and Join the Discussion!